Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma
Xīn Gào(Qingdao University), Rupal S. Bhatt(Dana-Farber Cancer Institute), Sabina Signoretti(Brigham and Women's Hospital), Toni K. Choueiri(Harvard University), Rana R. McKay(University of California San Diego), David F. McDermott(Beth Israel Deaconess Medical Center), Jesse Novak(Brigham and Women's Hospital), Paul J. Catalano(Computational Physics (United States)), Opeyemi A. Jegede(Dana-Farber Cancer Institute), David J. Kwiatkowski(Brigham and Women's Hospital), Connor Gray(Beth Israel Deaconess Medical Center), Daniel J. George(Duke University)
Cited by 8
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
The Immune Landscape of Cancer
|Immunity|2018|6.3k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k